– Un accord de licence volontaire non exclusif permet de fabriquer et de distribuer le lenacapavir pour la prévention du VIH et le traitement des patients ayant déjà reçu un traitement intensif et souffrant d’un VIH multirésistant aux médicaments HYDERABAD, Inde, 4 octobre 2024…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.